Evidence map›Paper›PMID 37886219›Full record

ArticleEpilepsy & behavior reports2023

Characteristics of an advanced epilepsy treatment gap in a region in Japan.

Tetsuhiro Fukuyama, Manami Yabe, Makoto Nishioka, Takenori Natsume, Yuumi Hoshino, Kohei Kanaya, Kyoko Takano, Norimoto Kobayashi, Yushi Inoue

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsy & behavior reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Tetsuhiro FukuyamaDepartment of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Manami YabeDepartment of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Makoto NishiokaDepartment of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Takenori NatsumeDepartment of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Yuumi HoshinoDivision of Epilepsy, Shinshu University Hospital, Matsumoto, Japan.
Kohei KanayaDivision of Epilepsy, Shinshu University Hospital, Matsumoto, Japan.
Kyoko TakanoCenter of Medical Genetics, Shinshu University Hospital, Matsumoto, Japan.
Norimoto KobayashiDepartment of Pediatrics, Nagano Red Cross Hospital, Nagano, Japan.
Yushi InoueNational Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Japan.
Shinshu University · JPNagano Red Cross Hospital · JPNational Epilepsy Center · JPShinshu University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the quality of epilepsy care in a region in Japan that lacked specialised care, we retrospectively evaluated patients who visited our newly established epilepsy division between April 2018 and March 2021, and had been treated with anti-seizure medications (ASMs) for at least 1 year prior. Of the 231 patients included, 169 had ongoing seizure episodes at first visit (seizure-persist group) and 62 had no seizure episodes for more than a year (seizure-free group). Eighty-three patients in the seizure-persist group had not received specialised epilepsy care, 15 had been treated with unnecessary medications, and seven had experienced side effects from ASMs. Twelve patients in the seizure-free group had been treated with unnecessary ASMs, 10 had been treated with ASMs with teratogenic potential and four had experienced ASM side effects. These patients could be classified as having an advanced epilepsy treatment gap (ETG) because they had not previously received necessary specialised care. The progressive decline in the number of patients with advanced ETG suggests that our new epilepsy division has addressed this issue. This study highlights that a significant number of patients with advanced ETGs exist in Japan and that proper countermeasures are required to address this gap.

Indexed as

Advanced epilepsy treatment gapEpilepsy care systemPseudo-drug-resistant epilepsySpecialised epilepsy care

Identifiers

PMID37886219
PMCPMC10598686
OpenAlexW4387675920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.